You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

16th International Hemophilia Congress in Turkey

A scientific symposium on the prevention and eradication of inhibitors in patients affected by Hemophilia A

read more 

EVENTS

EIGHT, the global educational initiative on Hemophilia A and its treatment

Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

read more 

EVENTS

Kedrion Biopharma participates in the Mother and Child Conference in Moscow

A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

read more 
  1. CORPORATE - 19-04-2017

    Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)

    The agreement aims to improve patient access to coagulation disorders treatments in Europe

    read more 
  2. EVENTS - 14-04-2017

    Kedrion Biopharma initiatives for World Hemophilia Day 2017

    The goal is to provide wider access to plasma-derived therapies for coagulation disorders the world over

    read more 
  3. CORPORATE - 24-03-2017

    New company AO Kirov Plasma established in Russia

    It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard

    read more 
  4. PLASMA & BIOTHERAPIES - 22-03-2017

    Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”

    International medical journal hosts review of contract plasma fractionation dynamics

    read more 

Pages

For more information please contact: pressoffice@kedrion.com